iBio announces production of biosimilar rituximab drug, shares rally Proactive Investors UK iBio (AMEX:IBIO) shares rallied around 10% Wednesday after the company announced that its proprietary iBioLaunch technology has been used to produce a functional, monoclonal antibody copy of rituximab, which is used to treat lymphomas, ... |
